Director, Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, Abbott Northwestern Hospital
Allina Health Minneapolis Heart Institute
Minneapolis, Minnesota, United States
Dr. Sorajja has expertise in valvular and structural heart disease and interventional cardiology. Dr. Sorajja is the national P.I. for multiple clinical trials, including TRILUMINATE, SUMMIT-MAC, EXPAND II, vDyne EFS, and SOAR-EFS. He is highly active in intellectural property development, and has published over 300 manuscripts and book chapters.
Disclosure(s): LAZA: Consulting Fees (e.g., advisory boards) (Ongoing)
Saturday, March 8, 2025
4:34 PM – 5:00 PM ET
Cephea | Design Features and EFS Trial Status
Sunday, March 9, 2025
9:43 AM – 9:51 AM ET
Sunday, March 9, 2025
10:06 AM – 10:36 AM ET
Anatomy, Indications, and Outcomes for Tricuspid TEER for Incomplete Coaptation
Sunday, March 9, 2025
1:46 PM – 1:54 PM ET
Panel Discussion How to Select Best Candidates for Tricuspid Repair/Replacement
Sunday, March 9, 2025
2:42 PM – 3:00 PM ET
Live Case Broadcasting from Piedmont | Atlanta, GA
Sunday, March 9, 2025
3:00 PM – 3:45 PM ET
Sunday, March 9, 2025
3:45 PM – 3:53 PM ET
Panel Discussion | Are we Ready for Repair and Replacement of Tricuspid Disease
Sunday, March 9, 2025
4:25 PM – 4:45 PM ET
Live Cases from Los Robles Regional Medical Center | Los Angeles, CA
Sunday, March 9, 2025
4:45 PM – 5:30 PM ET
Longer-Term Outcomes with AMEND Mitral Annuloplasty | First-in-Human Cohort
Monday, March 10, 2025
12:03 PM – 12:11 PM ET
Monday, March 10, 2025
2:10 PM – 2:20 PM ET